Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA Highlights XPERIENCE meets large unmet need – market leading performance in reduction of all tested pathogens Commercial sales in the USA to commence immediately $15B per annum total addressable market SYDNEY--(BUSINESS WIRE)--Next Science Limited (ASX:NXS) ( Next Science / Company) is pleased to announce that it has received a section 510(k) clearance from the Food and Drug Administration (FDA) for the sale of XPERIENCE No Rinse Antimicrobial Solution as a medical device in the United States. Sales of XPERIENCE in the US will commence immediately.